Acumen Pharmaceuticals, Inc.
sabirnetug
Alzheimer's disease
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for sabirnetug in Alzheimer's disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Phase 2 (IV) topline results expected late 2026”